Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Sanofi-aventis on Agreement with Æterna Zentaris


SAN FRANCISCO, CA, March 17, 2009 — Sanofi-aventis U.S. and Æterna Zentaris GmbH have signed an agreement for the development, registration and marketing for cetrorelix for the treatment of benign prostatic hyperplasia (BPH) for the US market. Under the terms of the agreement sanofi-aventis will make upfront and future milestone payments, and Æterna Zentaris will be eligible for royalties on future project sales. Covington & Burling LLP advised sanofi-aventis on the agreement.

Cetrorelix is in Phase 3 trials for treatment of BPH, a non-cancerous enlargement of the prostate. Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improves the lives of patients. Æterna Zentaris is a global biopharmaceutical company focused on endocrine therapy and oncology.

The Covington corporate team was led by partner Amy Toro and included associate Chelsea Tanaka-Delgado. Both are based in the firm’s San Francisco office.

Share this article: